Bavarian Nordic A/S (CPH:BAVA)

Market Cap	12.36B
Revenue (ttm)	5.72B
Net Income (ttm)	987.98M
Shares Out	77.81M
EPS (ttm)	12.60
PE Ratio	12.61
Forward PE	13.35
Dividend	n/a
Ex-Dividend Date	n/a

Volume	108,713
Average Volume	261,010
Open	157.05
Previous Close	158.90
Day's Range	152.70 - 158.00
52-Week Range	143.40 - 300.00
Beta	1.68
RSI	36.96
Earnings Date	Mar 5, 2025

About Bavarian Nordic

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the Unite...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1992
• Employees: 1,605
• Stock Exchange: Copenhagen Stock Exchange
• Ticker Symbol: BAVA

Financial Performance

In 2024, Bavarian Nordic's revenue was 5.72 billion, a decrease of -19.06% compared to the previous year's 7.06 billion. Earnings were 987.98 million, a decrease of -33.03%.